SunTrust Banks, Inc. initiated coverage on shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) in a research note published on Wednesday morning, Marketbeat reports. The brokerage issued a buy rating and a $26.00 target price on the biopharmaceutical company’s stock. SunTrust Banks also issued estimates for Abeona Therapeutics’ Q3 2017 earnings at ($0.23) EPS, Q4 2017 earnings at ($0.24) EPS, FY2017 earnings at ($0.81) EPS, Q1 2018 earnings at ($0.25) EPS, Q2 2018 earnings at ($0.30) EPS, Q3 2018 earnings at ($0.30) EPS, Q4 2018 earnings at ($0.28) EPS, FY2018 earnings at ($1.13) EPS, FY2019 earnings at ($1.09) EPS, FY2020 earnings at ($1.04) EPS and FY2021 earnings at ($0.80) EPS.

A number of other analysts also recently weighed in on the stock. HC Wainwright reaffirmed a buy rating and set a $30.00 price target (up previously from $20.00) on shares of Abeona Therapeutics in a report on Monday, October 16th. Cantor Fitzgerald upped their price target on shares of Abeona Therapeutics from $21.00 to $34.00 and gave the stock an overweight rating in a report on Wednesday, October 11th. Citigroup Inc. began coverage on shares of Abeona Therapeutics in a report on Tuesday, October 10th. They set a buy rating and a $32.00 price target for the company. Royal Bank Of Canada began coverage on shares of Abeona Therapeutics in a report on Thursday, September 14th. They set an outperform rating and a $23.00 price target for the company. Finally, Maxim Group set a $17.00 price target on shares of Abeona Therapeutics and gave the stock a buy rating in a report on Tuesday, August 29th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. Abeona Therapeutics presently has an average rating of Buy and a consensus target price of $22.90.

Shares of Abeona Therapeutics (ABEO) traded up $0.45 during trading on Wednesday, hitting $15.25. 631,700 shares of the stock were exchanged, compared to its average volume of 1,274,200. Abeona Therapeutics has a 12 month low of $4.05 and a 12 month high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.07). Abeona Therapeutics had a negative return on equity of 26.66% and a negative net margin of 2,746.38%. The firm had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.21 million. research analysts forecast that Abeona Therapeutics will post -0.7 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Abeona Therapeutics Inc. (ABEO) Now Covered by SunTrust Banks, Inc.” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.watchlistnews.com/abeona-therapeutics-inc-abeo-now-covered-by-suntrust-banks-inc/1698607.html.

A number of hedge funds have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN increased its position in Abeona Therapeutics by 3,421.8% during the 3rd quarter. Wells Fargo & Company MN now owns 35,218 shares of the biopharmaceutical company’s stock worth $600,000 after purchasing an additional 34,218 shares in the last quarter. EAM Investors LLC acquired a new position in Abeona Therapeutics during the 3rd quarter worth approximately $2,509,000. Ardsley Advisory Partners increased its position in Abeona Therapeutics by 33.3% during the 2nd quarter. Ardsley Advisory Partners now owns 60,000 shares of the biopharmaceutical company’s stock worth $383,000 after purchasing an additional 15,000 shares in the last quarter. California State Teachers Retirement System acquired a new position in Abeona Therapeutics during the 2nd quarter worth approximately $275,000. Finally, State Street Corp acquired a new position in Abeona Therapeutics during the 2nd quarter worth approximately $1,900,000. Institutional investors and hedge funds own 33.35% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.